$7.1 Billion is the total value of Baker Brothers Advisors's 95 reported holdings in Q4 2013. The portfolio turnover from Q3 2013 to Q4 2013 was 32.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PCYC | Sell | Pharmacyclics Inc. | $922,319,000 | -26.0% | 8,719,218 | -3.2% | 13.00% | -26.6% |
| SGEN | Buy | Seattle Genetics Inc. | $827,156,000 | -2.3% | 20,735,926 | +7.3% | 11.66% | -3.2% |
| INCY | Incyte Corp. | $749,859,000 | +32.7% | 14,810,559 | 0.0% | 10.57% | +31.6% | |
| GEVA | Synageva Biopharma Corp. | $664,880,000 | +2.1% | 10,273,182 | 0.0% | 9.37% | +1.2% | |
| ACAD | Acadia Pharmaceuticals Inc. | $498,679,000 | -9.0% | 19,955,126 | 0.0% | 7.03% | -9.8% | |
| Salix 2.75% 5/15/15conv bonds | $431,748,000 | +28.8% | 219,440,000 | 0.0% | 6.08% | +27.7% | ||
| GHDX | Genomic Health Inc. | $399,560,000 | -4.3% | 13,650,835 | 0.0% | 5.63% | -5.1% | |
| New | Incyte Genomics Notes 1.25% 11/15/2020 144Aconv bonds | $333,004,000 | – | 274,500,000 | +100.0% | 4.69% | – | |
| New | Incyte Genomics Notes 0.375% 11/15/2018 144Aconv bonds | $310,045,000 | – | 259,000,000 | +100.0% | 4.37% | – | |
| Sell | Incyte Genomics Notes 4.75% 10/1/2015 144Aconv bonds | $233,032,000 | -66.1% | 40,446,000 | -74.4% | 3.28% | -66.4% | |
| XOMA | Xoma Corp. | $155,008,000 | +49.9% | 23,032,372 | 0.0% | 2.18% | +48.6% | |
| BMRN | Buy | Biomarin Pharmaceuticals | $136,571,000 | +141.6% | 1,941,304 | +147.8% | 1.92% | +139.7% |
| Auxilium 1.5% 7/15/2018conv bonds | $96,343,000 | +6.8% | 87,090,000 | 0.0% | 1.36% | +5.8% | ||
| HALO | Sell | Halozyme Therapeutics Inc. | $94,392,000 | +21.8% | 6,297,026 | -10.3% | 1.33% | +20.8% |
| Biomarin Pharmaceuticals Notes 1.875% 4/23/2017conv bonds | $79,367,000 | -3.2% | 22,898,000 | 0.0% | 1.12% | -4.0% | ||
| Gilead 1.625% 5/1/16conv bonds | $70,910,000 | +19.1% | 21,500,000 | 0.0% | 1.00% | +18.1% | ||
| VNDA | Vanda Pharmaceuticals, Inc. | $59,459,000 | +13.3% | 4,791,179 | 0.0% | 0.84% | +12.3% | |
| Medivation 2.625% 4/1/17conv bonds | $57,806,000 | +4.0% | 39,500,000 | 0.0% | 0.82% | +3.2% | ||
| Intermune Inc Notes 2.5% 12/15/17conv bonds | $56,157,000 | -3.9% | 41,000,000 | 0.0% | 0.79% | -4.7% | ||
| CERS | Cerus | $54,537,000 | -4.0% | 8,455,306 | 0.0% | 0.77% | -4.8% | |
| BCRX | Biocryst Pharmaceuticals Inc. | $50,920,000 | +4.4% | 6,699,979 | 0.0% | 0.72% | +3.6% | |
| RPRX | Repros Therapeutics | $50,849,000 | -31.7% | 2,778,654 | 0.0% | 0.72% | -32.2% | |
| QCOR | Buy | Questcor Pharmaceuticals, Inc. | $42,246,000 | +33.4% | 775,864 | +42.1% | 0.60% | +32.2% |
| ANAC | New | Anacor Pharmaceuticals | $41,950,000 | – | 2,500,000 | +100.0% | 0.59% | – |
| GILD | Sell | Gilead Sciences Inc. | $41,764,000 | -46.7% | 556,108 | -55.4% | 0.59% | -47.1% |
| MRTX | Buy | Mirati Therapeutics Inc. | $39,581,000 | +31.9% | 2,380,074 | +20.2% | 0.56% | +31.0% |
| AEGR | Sell | Aegerion Pharmaceuticals | $35,480,000 | -49.6% | 500,000 | -39.0% | 0.50% | -50.0% |
| ARWR | Sell | Arrowhead Research Corp. | $33,527,000 | +87.6% | 3,090,000 | -1.6% | 0.47% | +85.8% |
| CLVS | Buy | Clovis Oncology | $31,988,000 | +74.4% | 530,738 | +75.9% | 0.45% | +72.8% |
| DSCI | Derma Sciences | $27,687,000 | -12.6% | 2,558,857 | 0.0% | 0.39% | -13.3% | |
| CHTP | Chelsea Therapeutics | $25,700,000 | +48.3% | 5,794,753 | 0.0% | 0.36% | +47.2% | |
| MDVN | Medivation Inc. | $25,421,000 | +6.5% | 398,331 | 0.0% | 0.36% | +5.6% | |
| ICPT | Intercept Pharmaceuticals, Inc. | $24,775,000 | -1.1% | 362,847 | 0.0% | 0.35% | -2.0% | |
| New | Salix 1.5% 3/15/19conv bonds | $22,369,000 | – | 15,000,000 | +100.0% | 0.32% | – | |
| PGNX | Progenics Pharmaceuticals, Inc. | $22,386,000 | +6.2% | 4,200,000 | 0.0% | 0.32% | +5.0% | |
| Intermune Inc Notes 5% 3/1/15conv bonds | $19,526,000 | -2.6% | 16,860,000 | 0.0% | 0.28% | -3.5% | ||
| AVNR | Buy | Avanir Pharmaceuticals | $18,240,000 | -2.6% | 5,428,591 | +22.6% | 0.26% | -3.4% |
| DYAX | New | Dyax Corp. | $15,270,000 | – | 2,026,537 | +100.0% | 0.22% | – |
| IDRA | Sell | Idera Pharmaceuticals Inc. | $14,685,000 | +43.9% | 3,171,765 | -45.9% | 0.21% | +42.8% |
| SGYPQ | Synergy Pharmaceuticals | $14,685,000 | +23.2% | 2,608,271 | 0.0% | 0.21% | +22.5% | |
| INSM | Sell | Insmed Inc. | $13,538,000 | -8.3% | 796,378 | -15.8% | 0.19% | -9.0% |
| New | Biomarin Pharmaceuticals Notes 0.75% 10/15/2018conv bonds | $13,262,000 | – | 12,500,000 | +100.0% | 0.19% | – | |
| STML | Sell | Stemline Therapeutics Inc. | $13,231,000 | -63.5% | 675,042 | -15.7% | 0.19% | -63.9% |
| KYTH | Buy | Kythera Biopharmaceuticals | $11,698,000 | -3.2% | 313,191 | +18.2% | 0.16% | -4.1% |
| ISIS | Isis Pharmaceuticals | $9,842,000 | +6.1% | 247,036 | 0.0% | 0.14% | +5.3% | |
| ZGNX | Buy | Zogenix, Inc. | $9,463,000 | +155.5% | 2,751,000 | +37.5% | 0.13% | +150.9% |
| PRTA | Sell | Prothena Corp. PLC | $8,935,000 | +19.5% | 336,918 | -8.9% | 0.13% | +18.9% |
| New | Infinity Pharmaceuticals Inc. | $8,883,000 | – | 643,256 | +100.0% | 0.12% | – | |
| THLD | Threshold Pharma | $8,651,000 | +0.4% | 1,852,399 | 0.0% | 0.12% | 0.0% | |
| QLTI | QLT, Inc. | $8,555,000 | +20.3% | 1,535,863 | 0.0% | 0.12% | +19.8% | |
| TGTX | Buy | TG Therapeutics | $8,579,000 | +183.7% | 2,199,656 | +266.6% | 0.12% | +181.4% |
| DSCO | Buy | Discovery Laboratories Inc. | $8,367,000 | +181.1% | 3,718,617 | +144.9% | 0.12% | +181.0% |
| ARRY | Array Biopharma Inc. | $7,515,000 | -19.5% | 1,500,000 | 0.0% | 0.11% | -20.3% | |
| AMBI | Sell | Ambit Biosciences Corp. | $7,210,000 | -37.8% | 747,954 | -0.0% | 0.10% | -38.2% |
| OMER | Omeros Corp | $6,869,000 | +15.8% | 608,404 | 0.0% | 0.10% | +15.5% | |
| NVAX | Sell | Novavax | $6,589,000 | +21.8% | 1,286,913 | -25.0% | 0.09% | +20.8% |
| IRWD | Buy | Ironwood Pharmaceuticals | $6,341,000 | +16.1% | 546,160 | +18.4% | 0.09% | +14.1% |
| OSIR | Osiris Therapeutics Inc. | $6,035,000 | -3.4% | 375,282 | 0.0% | 0.08% | -4.5% | |
| XNPT | Xenoport | $5,946,000 | +1.2% | 1,034,112 | 0.0% | 0.08% | +1.2% | |
| SGMO | Buy | Sangamo | $5,894,000 | +217.9% | 424,308 | +140.1% | 0.08% | +219.2% |
| PTLA | Sell | Portola Pharmaceuticals, Inc. | $5,779,000 | -28.0% | 224,434 | -25.2% | 0.08% | -28.9% |
| AERI | New | Aerie Pharmaceuticals | $5,388,000 | – | 300,000 | +100.0% | 0.08% | – |
| XNCR | New | Xencor | $5,027,000 | – | 550,000 | +100.0% | 0.07% | – |
| BDSI | BioDelivery Sciences Intl. Inc. | $4,983,000 | +8.5% | 846,005 | 0.0% | 0.07% | +7.7% | |
| AGIO | Buy | Agios Pharmaceuticals | $4,928,000 | -11.9% | 205,750 | +2.9% | 0.07% | -12.7% |
| BOTA | New | Biota Pharmaceuticals | $4,735,000 | – | 1,130,113 | +100.0% | 0.07% | – |
| VTUS | Ventrus Biosciences, Inc. | $4,645,000 | +32.2% | 1,215,840 | 0.0% | 0.06% | +30.0% | |
| EPZM | Buy | Epizyme Inc. | $4,576,000 | +472.0% | 220,000 | +1000.0% | 0.06% | +481.8% |
| TKMR | New | Tekmire Pharmaceuticals Corp. | $3,985,000 | – | 500,000 | +100.0% | 0.06% | – |
| GWPH | New | GW Pharmaceuticals PLCads | $3,912,000 | – | 94,172 | +100.0% | 0.06% | – |
| LGND | Ligand Pharmaceuticals Inc.class b | $3,861,000 | +21.5% | 73,400 | 0.0% | 0.05% | +20.0% | |
| OPHT | New | Ophthotech Corp. | $3,333,000 | – | 103,040 | +100.0% | 0.05% | – |
| ENTA | Sell | Enanta Pharmaceuticals | $2,976,000 | +3.9% | 109,097 | -12.7% | 0.04% | +2.4% |
| RCPT | Receptos Inc. | $2,899,000 | +11.6% | 100,000 | 0.0% | 0.04% | +10.8% | |
| MGNX | New | Macrogenics | $2,743,000 | – | 100,000 | +100.0% | 0.04% | – |
| SNTA | Synta Pharmaceuticals | $2,620,000 | -17.0% | 500,000 | 0.0% | 0.04% | -17.8% | |
| PBYI | Sell | Puma Biotechnology | $2,588,000 | -51.8% | 25,000 | -75.0% | 0.04% | -52.6% |
| BLUE | Buy | Bluebird Bio Inc. | $2,401,000 | -20.2% | 114,461 | +2.6% | 0.03% | -20.9% |
| UTHR | Sell | United Therapeutics Corp. | $2,262,000 | -48.8% | 20,000 | -64.3% | 0.03% | -49.2% |
| ITMN | New | Intermune Inc. | $2,210,000 | – | 150,000 | +100.0% | 0.03% | – |
| GERN | Sell | Geron Corp. | $1,908,000 | -43.0% | 402,629 | -59.7% | 0.03% | -43.8% |
| OSUR | Orasure Technologies Inc. | $1,531,000 | +4.6% | 243,467 | 0.0% | 0.02% | +4.8% | |
| ACHN | Achillion | $1,510,000 | +9.9% | 455,000 | 0.0% | 0.02% | +5.0% | |
| KPTI | New | Karyopharm Therapeutics | $1,406,000 | – | 61,330 | +100.0% | 0.02% | – |
| RIGL | Rigel Pharmaceuticals | $1,425,000 | -20.4% | 500,000 | 0.0% | 0.02% | -20.0% | |
| FOLD | Amicus Therapeutics | $1,210,000 | +1.3% | 515,072 | 0.0% | 0.02% | 0.0% | |
| XLRN | New | Acceleron Pharma Inc. | $1,188,000 | – | 30,000 | +100.0% | 0.02% | – |
| ZIOP | Ziopharm Oncology Inc. | $1,103,000 | +10.1% | 254,199 | 0.0% | 0.02% | +14.3% | |
| TSRO | Tesaro Inc. | $882,000 | -27.0% | 31,218 | 0.0% | 0.01% | -29.4% | |
| GALT | New | Galectin Therapeutics Inc. | $813,000 | – | 100,600 | +100.0% | 0.01% | – |
| FMI | New | Foundation Medicine Inc. | $476,000 | – | 20,000 | +100.0% | 0.01% | – |
| SLXP | Salix Pharmaceuticals, Inc. | $326,000 | +34.7% | 3,621 | 0.0% | 0.01% | +66.7% | |
| FPRX | New | Five Prime Therapeutics Inc. | $333,000 | – | 19,823 | +100.0% | 0.01% | – |
| CCXI | Sell | Chemocentryx Inc. | $290,000 | -73.9% | 50,000 | -75.0% | 0.00% | -75.0% |
| CYCCP | Cyclacel Pharmaceuticals Pfd. Conv. Ex 6%pfd conv ex | $193,000 | +9.0% | 20,979 | 0.0% | 0.00% | 0.0% | |
| CBST | Exit | Cubist Pharmaceuticals Inc. | $0 | – | -5,000 | -100.0% | -0.01% | – |
| MEIP | Exit | MEI Pharma, Inc. | $0 | – | -345,317 | -100.0% | -0.06% | – |
| Exit | Anacor Pharmaceuticals | $0 | – | -876,463 | -100.0% | -0.13% | – | |
| INFI | Exit | Infinity Pharmaceuticals Inc. | $0 | – | -586,936 | -100.0% | -0.14% | – |
| TRGT | Exit | Targacept | $0 | – | -2,068,186 | -100.0% | -0.16% | – |
| ARIA | Exit | Ariad Pharmaceuticals Inc. | $0 | – | -1,333,703 | -100.0% | -0.35% | – |
| VPHM | Exit | Viropharma Inc. | $0 | – | -5,592,239 | -100.0% | -3.12% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-02-14
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.